Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model
Authors:
- Marcelo Leite Vieira CostaMCMarcelo Leite Vieira Costa
- Roberto César Pereira Lima-JúniorRoberto César Pereira Lima-Júnior
- Karoline Sabóia AragãoKAKaroline Sabóia Aragão
- Raul Pinheiro MedeirosRMRaul Pinheiro Medeiros
- Raphael Dias Marques-NetoRMRaphael Dias Marques-Neto
- Lucas de Sá GrassiLGLucas de Sá Grassi
- Leandro Linhares LeiteLLLeandro Linhares Leite
- Lorena Guimaraes NunesLNLorena Guimaraes Nunes
- José Wilson Benevides de Mesquita NetoJNJosé Wilson Benevides de Mesquita Neto
- Gerly Anne de Castro BritoGBGerly Anne de Castro Brito
- Marcellus Henrique Loiola Pontes de SouzaMSMarcellus Henrique Loiola Pontes de Souza
- Paulo Roberto Carvalho de AlmeidaPAPaulo Roberto Carvalho de Almeida
- 1 August 2014
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 74 (4) , 711-720
Abstract
Nonalcoholic steatohepatitis (NASH) has been associated with irinotecan (IRI)-based cancer chemotherapy regimens. The purpose of this study was to propose and test a consistent model of IRI-induced NASH, filling a gap in the medical literature. Swiss male mice were distributed in groups (n = 8) and injected with saline (5 mL/kg, i.p.; control) or IRI (25, 50, 75 or 100 mg/kg, i.p.) thrice a week for 7 weeks. Blood samples were collected to measure the serum concentrations of proteins, alanine and aspartate aminotransferases (ALT and AST). Each week animals were euthanized, and the livers were submitted to myeloperoxidase (MPO) assay, lipid dosage, immunohistochemistry for inducible nitric oxide synthase (iNOS), TNF-α and interleukin-1β (IL-1β), and histopathological analysis. Survival rates were also determined. Mice treated with IRI had a significantly (p < 0.05) lower survival rate than controls and time- and dose-dependent body weight loss. ALT and AST plasma levels increased in relation to controls only in mice receiving IRI 50 mg/kg (p < 0.05). The histopathological features characteristic of NASH was observed, including steatosis, lobular neutrophil infiltration and ballooning hepatocytic degeneration. Additional findings included increased MPO, lipid accumulation, portal neutrophil infiltration, IL-1β and iNOS expression and fibrosis in liver tissues and low serum protein levels compared to controls. This is the first report of a consistent model of IRI-induced NASH capable of mimicking clinical findings.Keywords
This publication has 26 references indexed in Scilit:
- Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single InstitutionJournal of the American College of Surgeons, 2010
- Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastasesBritish Journal of Surgery, 2007
- Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal MetastasesJournal of Clinical Oncology, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Tumor Progression While on ChemotherapyAnnals of Surgery, 2004
- Non‐alcoholic fatty liver disease: An overviewJournal of Gastroenterology and Hepatology, 2002
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological LesionsAmerican Journal of Gastroenterology, 1999
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- Resection of Nonresectable Liver Metastases from Colorectal Cancer After Neoadjuvant ChemotherapyAnnals of Surgery, 1996